OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS TREATED IN A BRAZILIAN PUBLIC CANCER CENTER – A REAL WORLD EXPERIENCE OF 809 PATIENTS IN A 11 YEAR PERIOD

OUTCOMES OF DIFFUSE LARGE B CELL LYMPHOMA PATIENTS TREATED IN A BRAZILIAN PUBLIC CANCER CENTER – A REAL WORLD EXPERIENCE OF 809 PATIENTS IN A 11 YEAR PERIOD

Introduction: Diffuse Large B Cell Lymphoma (DLBCL) is a heterogenous disease. Factors based on clinical and simple laboratory parameters are known and widely used such as the Revised International Prognostic Index (R-IPI) and National Comprehensive Cancer Network -IPI (NCCN-IPI). Thus, we aimed to...

Full description

Bibliographic Details
Main Authors: M Bellesso, J Pereira, L Bassolli, ANR Abdo, WFS Junior, RD Velasques, AAGS Brandão, LAPC Lage, FVR Maciel, V Rocha, H Visnadi
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137921003126

Internet

http://www.sciencedirect.com/science/article/pii/S2531137921003126

Similar Items